Experience with ifosfamide in paediatric tumours

Cancer Chemother Pharmacol. 1989:24 Suppl 1:S28-9. doi: 10.1007/BF00253235.

Abstract

Ifosfamide, alone or in combination, is used in a variety of childhood tumours. Soft-tissue sarcomas are especially sensitive, with a 78% actuarial survival. Hyperaminoaciduria and a brief transient decrease in the plasma level of certain amino acids are the earliest signs of tubular toxicity.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Drug Evaluation
  • Humans
  • Ifosfamide / adverse effects
  • Ifosfamide / therapeutic use*
  • Neoplasms / drug therapy*

Substances

  • Ifosfamide